Affiliations: [a] Department of Neuroradiology, Hospital Quirón, Zaragoza, Spain | [b] Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain
Correspondence:
[*]
Correspondence to: Dr. P.J. Modrego, Department of Neurology, Hospital Miguel Servet, 50009 Zaragoza, Spain. E-mail: pmodrego@salud.aragon.es.
Abstract: Alzheimer's disease (AD) is the most common cause of dementia in elderly people in western countries. However important goals are unmet in the issue of early diagnosis and the development of new drugs for treatment. Magnetic resonance imaging (MRI) and volumetry of the medial temporal lobe structures are useful tools for diagnosis. Positron emission tomography is one of the most sensitive tests for making an early diagnosis of AD but the cost and limited availability are important caveats for its utilization. The importance of magnetic resonance techniques has increased gradually to the extent that most clinical works based on AD use these techniques as the main aid to diagnosis. However, the accuracy of structural MRI as biomarker of early AD generally reaches an accuracy of 80%, so additional biomarkers should be used to improve predictions. Other structural MRI (diffusion weighted, diffusion-tensor MRI) and functional MRI have also added interesting contribution to the understanding of the pathophysiology of AD. Magnetic resonance spectroscopy has proven useful to monitor progression and response to treatment in AD, as well as a biomarker of early AD in mild cognitive impairment.
Keywords: Alzheimer's disease, diffusion, functional, magnetic resonance, monitoring of treatment, perfusion, spectroscopy, structural image
